CSF Aβ42 predicts early-onset dementia in Parkinson disease

Neurology

Volumn 82, Issue 20, 2014, Pages 1784-1790

  Alves, Guido ^a   Lange, Johannes ^a   Blennow, Kaj ^b   Zetterberg, Henrik ^b,c   Andreasson, Ulf ^b   Førland, Marthe G ^a   Tysnes, Ole Bjørn ^d,e   Larsen, Jan P ^a,f   Pedersen, Kenn F ^a  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY OF STAVANGER   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42];

AGED; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COGNITION; DEMENTIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH RISK PATIENT; HUMAN; IN VIVO STUDY; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVE FIBER DEGENERATION; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; AMYLOID BETA-PEPTIDES; DEMENTIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; PEPTIDE FRAGMENTS; PROGNOSIS; RISK;

EID: 84902173245     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000425     Document Type: Article

References (40)

1. Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. Lancet Neurol 2012;11:697-707.
2. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011;122:187-204.
3. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115:409-415.
4. Masliah E, Rockenstein E, Veinbergs I, et al. Beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. Proc Natl Acad Sci U S A 2001;98:12245-12250.
5. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006;67:1931-1934.
6. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134:1493-1505.
7. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloid-neuropathology in a populationbased autopsy study. Neurology 2003;60:652-656.
8. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 2006;59:512-519.
9. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-128.
10. Compta Y, Marti MJ, Ibarretxe-Bilbao N, et al. Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov Disord 2009;24:2203-2210.
11. Montine TJ, Shi M, Quinn JF, et al. CSF Abeta(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord 2010;25:2682-2685.
12. Parnetti L, Tiraboschi P, Lanari A, et al. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 2008; 64:850-855.
13. Mollenhauer B, Trenkwalder C, von Ahsen N, et al. Betaamyloid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement Geriatr Cogn Disord 2006;22:200-208.
14. Alves G, Bronnick K, Aarsland D, et al. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian Park West study. J Neurol Neurosurg Psychiatry 2010;81:1080-1086.
15. Parnetti L, Castrioto A, Chiasserini D, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol 2013;9:131-140.
16. Siderowf A, Xie SX, Hurtig H, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010;75:1055-1061.
17. Compta Y, Pereira JB, Rios J, et al. Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat Disord 2013;19:717-724.
18. Alves G, Muller B, Herlofson K, et al. Incidence of Parkinson's disease in Norway: the Norwegian Park West study. J Neurol Neurosurg Psychiatry 2009;80:851-857.
19. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-39.
20. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992;42:1142-1146.
21. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne DM, Lieberman A, eds. Recent Development in Parkinson's Disease. Florham Park: MacMillan Health Care Information; 1987:153-163.
22. Hoehn M, Yahr M. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
23. Folstein M, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
24. Litvan I, Goldman JG, Troster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012;27:349-356.
25. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131-144.
26. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707.
27. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology 2001;56: 730-736.
28. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-35.
29. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-393.
30. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-2969.
31. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392.
32. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008;23:837-844.
33. Pedersen KF, Larsen JP, Tysnes OB, Alves G. Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian Park West Study. JAMA Neurol 2013;70: 580-586.
34. Janvin CC, Larsen JP, Aarsland D, Hugdahl K. Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia. Mov Disord 2006;21: 1343-1349.
35. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of betaamyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98-106.
36. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795-804.
37. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228-234.
38. Gomperts SN, Locascio JJ, Rentz D, et al. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013;80:85-91.
39. Hurtado DE, Molina-Porcel L, Iba M, et al. A{beta} accelerates the spatiotemporal progression of tau pathology and augments tau amyloidosis in an Alzheimer mouse model. Am J Pathol 2010;177:1977-1988.
40. Clinton LK, Blurton-Jones M, Myczek K, Trojanowski JQ, LaFerla FM. Synergistic interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010;30:7281-7289.